InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,185.74
(
0.10%
)
US TECH 100
17,619.96
(
0.06%
)
Dow Jones
38,889.99
(
0.10%
)
Brent Oil
83.10
(
-0.46%
)
Bitcoin
63,104.91
(
-0.10%
)
Post# of 23979
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

buckiii2

Send PM Follow Ignore
Followers 59
Posts 4696
Boards Moderated 0
Alias Born 04/27/2009

buckiii2

Re: buckiii2 post# 23839

Friday, 11/10/2017 1:57:04 PM

Friday, November 10, 2017 1:57:04 PM

Post# of 23979
Title: Clinical and biomarker analyses of a phase II study of intratumoral tavokinogene telseplasmid (pIL-12) plus pembrolizumab in stage III/IV melanoma patients predicted to not respond to anti-PD-1

Poster Number: P524

Lead Author: Alain Algazi, MD, Associate Professor, Department of Medicine (Hematology/Oncology), UCSF

Date and Time: Saturday, November 11th, 12:30-2:00 p.m. and 6:30-8:00 p.m.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up